FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions relates to medicine, namely to infection diseases, hepatology, and can be applied for prevention or treatment of viral disease, caused by virus of hepatitis C. For this purpose therapeutic medication, as active ingredients in it are combined 22β-methoxyolean-12-en-3β,24(4β)-diol and interferon, is introduced to patient. High therapeutic effect of claimed medication is associated with synergetic effect of 22β-methoxyolean-12-en-3β,24(4β)-diol and interferon, manifested in inhibition of hepatitis C virus.
EFFECT: insuring high therapeutic effect.
6 cl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN INTERFERON-CONTAINING THERAPEUTIC COMPOSITION, INTERFERON-BASE PHARMACEUTICAL PREPARATION (VARIANTS) | 1993 |
|
RU2145235C1 |
| SINGLE NUCLEOTIDE POLYMORPHISM ON CHROMOSOME 15 ENABLING PREDICTION OF HCV TREATMENT RESPONSES | 2012 |
|
RU2606759C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN 1 FOR PREVENTION AND TREATMENT OF HEPATOCELLULAR CARCINOMA | 2016 |
|
RU2770021C2 |
| ANTIVIRAL NUCLEOSIDES | 2006 |
|
RU2422454C2 |
| PTERIDINES EFFECTIVE AS HCV INHIBITORS AND METHODS FOR PRODUCING PTERIDINES | 2006 |
|
RU2447074C2 |
| DOSAGE FORMS | 2005 |
|
RU2393863C2 |
| PYRIDO [2,3-d] PYRIMIDINES, USEFUL AS HCV INHIBITORS AND SYNTHESIS METHODS THEREOF | 2006 |
|
RU2444522C2 |
| APPLICATION OF MODIFIED CYCLOSPORINS FOR TREATING HCV INDUCED DISEASES | 2004 |
|
RU2389501C2 |
| DERIVATIVES OF (4-METHYLSULPHONYLAMINOPHENYL)-QUINOLINE, USEFUL IN TREATMENT OF HEPATITIS C | 2011 |
|
RU2572835C2 |
| ANTIVIRAL COMPOUND OF MULTIPLE ACTION, ITS COMPOSITION AND METHOD OF TREATING VIRAL DISEASES | 2012 |
|
RU2597150C2 |
